PCVX has 36-month beta value of 0.99. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PCVX is 120.32M, and currently, short sellers hold a 12.04% ratio of that float. The average trading volume of PCVX on February 05, 2025 was 1.32M shares.
PCVX) stock’s latest price update
The stock price of Vaxcyte Inc (NASDAQ: PCVX) has surged by 2.01 when compared to previous closing price of 84.81, but the company has seen a -6.09% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-30 that SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
PCVX’s Market Performance
PCVX’s stock has fallen by -6.09% in the past week, with a monthly rise of 3.86% and a quarterly drop of -18.65%. The volatility ratio for the week is 4.77% while the volatility levels for the last 30 days are 4.88% for Vaxcyte Inc The simple moving average for the past 20 days is -0.26% for PCVX’s stock, with a -1.05% simple moving average for the past 200 days.
Analysts’ Opinion of PCVX
Many brokerage firms have already submitted their reports for PCVX stocks, with Goldman repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Goldman is $135 based on the research report published on December 20, 2024 of the previous year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see PCVX reach a price target of $69. The rating they have provided for PCVX stocks is “Buy” according to the report published on December 07th, 2023.
PCVX Trading at -1.38% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.53% of loss for the given period.
Volatility was left at 4.88%, however, over the last 30 days, the volatility rate increased by 4.77%, as shares surge +1.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.65% lower at present.
During the last 5 trading sessions, PCVX fell by -6.10%, which changed the moving average for the period of 200-days by +38.57% in comparison to the 20-day moving average, which settled at $86.74. In addition, Vaxcyte Inc saw 5.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from Wassil Jim, who sale 8,000 shares at the price of $86.22 back on Feb 03 ’25. After this action, Wassil Jim now owns 205,695 shares of Vaxcyte Inc, valued at $689,790 using the latest closing price.
Wassil Jim, the Officer of Vaxcyte Inc, proposed sale 8,000 shares at $88.20 during a trade that took place back on Feb 03 ’25, which means that Wassil Jim is holding shares at $705,600 based on the most recent closing price.
Stock Fundamentals for PCVX
Current profitability levels for the company are sitting at:
- -36.62 for the present operating margin
- 0.03 for the gross margin
The net margin for Vaxcyte Inc stands at -35.14. The total capital return value is set at -0.15. Equity return is now at value -21.06, with -20.08 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.81. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -49.31.
Currently, EBITDA for the company is -464.88 million with net debt to EBITDA at 1.75. When we switch over and look at the enterprise to sales, we see a ratio of 675.67. The receivables turnover for the company is 0.81for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.88.
Conclusion
To put it simply, Vaxcyte Inc (PCVX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
